Roche subsidiary earns priority review status for drug Lucentis

Genentech, a member of Basel, Switzerland-based Roche Group, earned priority review status for its drug Lucentis.

The drug is intended to treat myopic choroidal neovascularization, a condition that can lead to vision loss or blindness.

The priority review process, which expedites the review of a drug application to about six months after filing, was created to decrease the time it takes to put new medicines on the market.

If approved, San Francisco-based Genentech would maintain all commercial rights to Lucentis in the U.S., while Roche would hold commercial rights outside the U.S.

More articles on supply chain:

St. Jude Medical issues warning on heart device after 2 patient deaths
Cost is king: 5 thoughts on the hospital supply chain from an expert who's seen both sides of the business
Red Cross stresses need for blood, platelets after hurricane cancels 40 blood drives

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months